Myriad Genetics, Inc. MYGN
Set alert
5.99 USD +0.14 +2.39%
As of Nov 3, 11:10 AM ET
5.87 Day range 6.08
2.74 52-week range 8.09
- YTD
- -2.60%
- 1 year
- -26.77%
- Open
- 5.87
- Prev close
- 5.85
- Mkt cap
- 572.94M
- Vol
- 187.73K
- Avg vol
- 2.32M
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.87
- High
- 6.08
- Forward P/E
- 71.53
- Beta
- 1.89
- Short ratio
- 4.83
- Inst. own
- 103.89%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 13.32
- 200-d avg
- 21.11
- 1y target
- 19.41
Analyst view
Consensus: buy
Buy
Price target (mean) 19.41 +224.1% upside
Now 5.99
- Target (low)
- 11.00
- Target (mean)
- 19.41
- Target (high)
- 29.00
Ratings (0m) 16 8 buy · 5 hold · 3 sell
- Strong buy4
- Buy4
- Hold5
- Sell1
- Strong sell2
Recommendation trend
- This month 16
- 1 month ago 16
- 2 months ago 16
- 3 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.06447 | -0.08 – -0.04 | -0.01 | -544.7% | 202.23M | +0.0% | 9 |
| Next quarter | 0.01984 | -0.03 – 0.09 | 0.05 | -60.3% | 212.77M | +0.6% | 9 |
| Current year | 0.05454 | -0.10 – 0.10 | 0.14 | -61.0% | 851.22M | +1.6% | 15 |
| Next year | 0.31561 | 0.12 – 0.69 | 0.05454 | +478.7% | 941.85M | +10.7% | 14 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 25, 2025 | Raymond James | Reiterated | Outperform | Outperform |
| Feb 25, 2025 | UBS | Maintained | Neutral | Neutral |
| Feb 12, 2025 | Craig-Hallum | Initiated | — | Buy |
| Jan 30, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Jan 28, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 16, 2025 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| Dec 13, 2024 | B of A Securities | Maintained | Underperform | Underperform |
| Dec 10, 2024 | UBS | Initiated | — | Neutral |
| Dec 9, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Nov 18, 2024 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Nov 11, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Sep 19, 2024 | Morgan Stanley | Initiated | — | Equal-Weight |
| Aug 27, 2024 | Wells Fargo | Initiated | — | Overweight |
| Aug 13, 2024 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Aug 13, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Aug 7, 2024 | TD Cowen | Maintained | Hold | Hold |
| Aug 7, 2024 | JP Morgan | Maintained | Underweight | Underweight |
| Jun 27, 2024 | Scotiabank | Initiated | — | Sector Outperform |
| May 13, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| May 8, 2024 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Jan 30, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 29, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 21, 2023 | Piper Sandler | Initiated | — | Neutral |
| Dec 19, 2023 | Wells Fargo | Initiated | — | Equal-Weight |
| Dec 14, 2023 | Guggenheim | Initiated | — | Buy |
| Dec 13, 2023 | Wolfe Research | Initiated | — | Outperform |
| Nov 7, 2023 | JP Morgan | Maintained | Underweight | Underweight |
| Aug 7, 2023 | JP Morgan | Maintained | Underweight | Underweight |
| Jul 24, 2023 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 21, 2023 | Goldman Sachs | Maintained | Buy | Buy |